These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16111198)

  • 1. [Immunologic tests: Membrane cofactor protein (MCP, CD46)].
    Shingai M; Seya T
    Nihon Rinsho; 2005 Jul; 63 Suppl 7():95-7. PubMed ID: 16111198
    [No Abstract]   [Full Text] [Related]  

  • 2. [Membrane cofactor protein (MCP, CD46)].
    Seya T
    Nihon Rinsho; 2010 Jun; 68 Suppl 6():98-101. PubMed ID: 20942011
    [No Abstract]   [Full Text] [Related]  

  • 3. [Immunological tests: Decay-accelerating factor].
    Negoro T; Tobe T
    Nihon Rinsho; 2005 Jul; 63 Suppl 7():98-100. PubMed ID: 16111199
    [No Abstract]   [Full Text] [Related]  

  • 4. [Membrane cofactor protein (MCP, CD46)].
    Seya T; Taniguchi M; Matsumoto M
    Nihon Rinsho; 1999 Nov; 57 Suppl():75-8. PubMed ID: 10635779
    [No Abstract]   [Full Text] [Related]  

  • 5. Protection of mammalian cells from complement-mediated lysis by transfection of human membrane cofactor protein and decay-accelerating factor.
    Oglesby TJ; White D; Tedja I; Liszewski K; Wright L; Van den Bogarde J; Atkinson JP
    Trans Assoc Am Physicians; 1991; 104():164-72. PubMed ID: 1726964
    [No Abstract]   [Full Text] [Related]  

  • 6. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome.
    Richards A; Kemp EJ; Liszewski MK; Goodship JA; Lampe AK; Decorte R; Müslümanoğlu MH; Kavukcu S; Filler G; Pirson Y; Wen LS; Atkinson JP; Goodship TH
    Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12966-71. PubMed ID: 14566051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunologic tests: C3].
    Kitano E; Kitamura H
    Nihon Rinsho; 2005 Jul; 63 Suppl 7():63-6. PubMed ID: 16111189
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical significance of membrane cofactor protein analysis].
    Seya T
    Nihon Rinsho; 1990 Feb; 48 Suppl():673-6. PubMed ID: 2355591
    [No Abstract]   [Full Text] [Related]  

  • 9. Human CD46 rather than CD55 is a key element in protection against complement activation in vitro.
    van Dixhoorn MG; Dekker S; Janssen RW; Verbakel CA; Grosveld F
    Transplant Proc; 2000 Aug; 32(5):916-8. PubMed ID: 10936272
    [No Abstract]   [Full Text] [Related]  

  • 10. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome.
    Fremeaux-Bacchi V; Moulton EA; Kavanagh D; Dragon-Durey MA; Blouin J; Caudy A; Arzouk N; Cleper R; Francois M; Guest G; Pourrat J; Seligman R; Fridman WH; Loirat C; Atkinson JP
    J Am Soc Nephrol; 2006 Jul; 17(7):2017-25. PubMed ID: 16762990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the promoter region of the membrane cofactor protein (CD46) gene of the human complement system and comparison to a membrane cofactor protein-like genetic element.
    Cui W; Hourcade D; Post T; Greenlund AC; Atkinson JP; Kumar V
    J Immunol; 1993 Oct; 151(8):4137-46. PubMed ID: 7691939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis.
    Brooimans RA; van Wieringen PA; van Es LA; Daha MR
    Eur J Immunol; 1992 Dec; 22(12):3135-40. PubMed ID: 1280224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32.
    Esparza-Gordillo J; Goicoechea de Jorge E; Buil A; Carreras Berges L; López-Trascasa M; Sánchez-Corral P; Rodríguez de Córdoba S
    Hum Mol Genet; 2005 Mar; 14(5):703-12. PubMed ID: 15661753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Properdin, factor H, factor I].
    Ohsawa I; Tomino Y
    Nihon Rinsho; 2010 Jun; 68 Suppl 6():77-81. PubMed ID: 20942006
    [No Abstract]   [Full Text] [Related]  

  • 15. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome.
    Richards A; Kathryn Liszewski M; Kavanagh D; Fang CJ; Moulton E; Fremeaux-Bacchi V; Remuzzi G; Noris M; Goodship TH; Atkinson JP
    Mol Immunol; 2007 Jan; 44(1-3):111-22. PubMed ID: 16882452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of defective complement control in hemolytic uremic syndrome.
    Zipfel PF; Misselwitz J; Licht C; Skerka C
    Semin Thromb Hemost; 2006 Mar; 32(2):146-54. PubMed ID: 16575689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue-specific expression of CD46 isoforms.
    Johnstone RW; Russell SM; Loveland BE; Jayasuriya N; McKenzie IF
    Transplant Proc; 1992 Oct; 24(5):2331-2. PubMed ID: 1413083
    [No Abstract]   [Full Text] [Related]  

  • 18. [CD46 deficiency].
    Hatanaka M; Seya T
    Ryoikibetsu Shokogun Shirizu; 2000; (32):239-42. PubMed ID: 11212706
    [No Abstract]   [Full Text] [Related]  

  • 19. Expression of membrane cofactor protein (MCP, CD46) in human liver diseases.
    Kinugasa N; Higashi T; Nouso K; Nakatsukasa H; Kobayashi Y; Ishizaki M; Toshikuni N; Yoshida K; Uematsu S; Tsuji T
    Br J Cancer; 1999 Aug; 80(11):1820-5. PubMed ID: 10468303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of membrane cofactor protein (CD46) in the human kidneys.
    Nakanishi I; Moutabarrik A; Hara T; Hatanaka M; Hayashi T; Syouji T; Okada N; Kitamura E; Tsubakihara Y; Matsumoto M
    Eur J Immunol; 1994 Jul; 24(7):1529-35. PubMed ID: 8026516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.